Bronchiolitis Obliterans Syndrome (BOS)
Bronchiolitis Obliterans Syndrome (BOS) Market

Bronchiolitis Obliterans Syndrome

Bronchiolitis Obliterans Syndrome (BOS) is an inflammatory condition that affects the lung’s tiniest airways, the bronchioles.


Bronchiolitis Obliterans Syndrome Epidemiology Segmentation


  • Incident Cases of Lung Transplant
  • Incident Cases of Hematopoietic Stem Cell Transplant
  • Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome after Lung Transplant
  • Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplants
  • Grade-wise Bronchiolitis Obliterans Syndrome Cases


Bronchiolitis Obliterans Syndrome Epidemiological Insights Observed in 2020


  • The total Bronchiolitis Obliterans Syndrome diagnosed prevalent population was found to be 31,570 in the 7MM countries.
  • Among the EU5 countries, the highest Bronchiolitis Obliterans Syndrome prevalent population with 3,422 cases was observed in Germany.
  • Spain was observed to have the lowest Bronchiolitis Obliterans Syndrome prevalent population with 1,653 cases.


Bronchiolitis Obliterans Syndrome Market Insights


The Bronchiolitis Obliterans Syndrome market size was found to be USD 218.7 million in the 7MM in 2020.


Bronchiolitis Obliterans Syndrome Market Drivers


  • Extracorporeal Photopheresis—a promising prospect
  • Upcoming launches and approval
  • Technological advancements


Bronchiolitis Obliterans Syndrome Market Barriers


  • Adverse events related to extensive use of off-label therapies
  • Complicated multidisciplinary care


Bronchiolitis Obliterans Syndrome Emerging Drugs


The emerging drugs in the Bronchiolitis Obliterans Syndrome market are


  • Liposomal Cyclosporine A
  • Jakafi
  • Esbriet, and several others


Key Bronchiolitis Obliterans Syndrome Companies


The key companies working in the Bronchiolitis Obliterans Syndrome market are


  • Zambon Pharma
  • Incyte Corporation
  • Genentech, and several others